J&J Projects More Than $100B in 2026 Sales as Oncology Growth Accelerates

By FieldPulse Staff · May 25, 2026

Tags: strategy, launch

J&J said it expects 2026 sales to exceed $100 billion, with oncology and immunology continuing to drive a large share of growth.

J&J said it expects 2026 sales to exceed $100 billion, with oncology and immunology remaining central growth engines inside the broader portfolio.

The forecast reflects management's confidence in the company's higher-growth specialty businesses and the continued performance of key branded assets.

The most useful interpretation is strategic concentration.

J&J is signaling that future growth is being driven by its strongest specialty franchises, which matters more than the headline scale on its own.